Anuh Pharma came up with another good set of results, with sales growing by 24% and EPS doubling. They are now guiding for 16% CAGR in their sales for next 5-years. I am sharing notes from their recent presentation.
FY24Q3
-
Planning to invest 20 Cr in existing site in FY25 for capacity enhancing by 70 KL
-
Focusing on deeper penetration in European markets
-
Added CEP for Ambroxol HCL (expected CEP for Allopurinol and Sulfadoxine)
-
Got Approval of Isoniazid from WHO PQ (TB product)
-
New product launches: Vildagliptin, Acebrophylline, Amodiquine, Moxifloxacin and Allopurinol. Expected to contribute 50 cr. in FY25
-
R&D pipeline: 6 new products in next 9 months
-
Guidance: 16% CAGR for next 5 years
-
Investing in solar power
-
Product mix: most growth was driven by acute portfolio
-
Africa has seen a huge drop in 9MFY24
Disclosure: Invested (position size here, no transactions in last-30 days)